Dose banding of intravenous ganciclovir: Banding scheme proposal and audit of toxicity and efficiency
| Autor: | Carmen López-Cabezas, E Calvo-Cidoncha, Dolors Soy-Muner, Montserrat Rodriguez-Reyes |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Ganciclovir medicine.medical_treatment Kidney Function Tests Antiviral Agents 030226 pharmacology & pharmacy Vial 03 medical and health sciences 0302 clinical medicine medicine Humans Pharmacology (medical) 030212 general & internal medicine Aged Pharmacology Chemotherapy Dose-Response Relationship Drug business.industry Body Weight Significant difference virus diseases Middle Aged Increased risk Anesthesia Toxicity Administration Intravenous Female business Intravenous ganciclovir medicine.drug |
| Zdroj: | Journal of Clinical Pharmacy and Therapeutics. 46:767-771 |
| ISSN: | 1365-2710 0269-4727 |
| Popis: | What is known and objective Dose banding is a strategy to optimize processing without reducing patient safety. Prescribed doses are rounded up or down to predetermined standard doses. Although it has been mostly used in chemotherapy, other drugs are suitable for this strategy, such as the antiviral ganciclovir. The aim of this work is to assess the safety and efficiency of a dose-rounding system for intravenous ganciclovir. Methods Dose bands were established for a maximum of 10% variation from the individualized dose. The number of annual preparations that expired before use and the number of ganciclovir vials saved were documented as indicators of efficiency. Toxicity was assessed comparing haematological parameters before and after ganciclovir treatment in a sample of patients who received doses above the theoretical dose (n = 121) and in the rest of the cohort (n = 129). Results and discussion Five ganciclovir standard doses were established. It was shown that the bulk of the preparations (83.7%) had a maximum variation between the exact dose prescribed and the adjusted dose of ±10%. Three years after its implementation, a mean of 2848 annual preparations were compounded. The average percentage of annual expired preparations was lower than 1% of the total compounded doses, and the dose-rounding system allowed for saving 699 manufactured ganciclovir vials annually. There was no significant difference between haemoglobin and leucocyte levels measured before and after ganciclovir treatment in both groups. What is new and conclusion Ganciclovir dose banding allows for efficient management of preparations without an increased risk of acute haematological side effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|